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 Floating matrix tablets of Lansoprezol were developed to prolong gastric 
residence time, leading to sustained action of the drug. Tablets were 
prepared by wet granulation technique, using hydroxypropylmethyl-
cellulose as a polymer in two different grades, HPMC K4M and HPMC K15M. 
Tablets were evaluated for their physical characteristics, viz., hardness, 
thickness, friability, mass variation, drug content and floating properties. 
Further, tablets were studied for in vitro drug release characteristics for 24 
hours. The tablets exhibited controlled and prolonged drug release profiles 
while floating over the dissolution medium. Non-Fickian diffusion was 
confirmed as the drug release mechanism from these tablets, indicating that 
water diffusion and polymer rearrangement played an essential role in drug 
release. The best formulation (F4) was selected based on in vitro 
characteristics and was used in vivo radiography studies by incorporating 
barium sulphate. These studies revealed that the tablets remained in the 
stomach for 12 hours in fasting rabbits and indicated that gastric retention 
time was increased by the floating principle, which was considered 
desirable for the absorption window drugs. 
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1.  Introduction 
In recent years, oral dosage forms for gastric 
retention have drawn more and more attention for their 
theoretical advantage in permitting control over the 
time and site of drug release. This is particularly valuable 
for drugs that exhibit an absorption window in the upper 
part of the small intestine and dissolve better in the 
acidic environment of the stomach (Zhenping et al., 
2001). Oral delivery of drugs is, by far, the most 
preferable route of drug delivery due to the ease of 
administration, patient compliance, and flexibility in 
formulation. A controlled drug delivery system with 
prolonged residence time in the stomach is of particular 
interest for drugs that are locally active in the stomach, 
using current release technology, oral delivery for 24 h is 
possible for many drugs; however, the substance must 
be well absorbed throughout the whole gastrointestinal 
tract. A significant obstacle may arise if there is a narrow 
window for drug absorption in the gastrointestinal tract 
(GIT), The real issue in the development of oral 
controlled release dosage forms is not just to prolong 
the delivery of the drugs for more than 12 h, but to 
prolong the presence of the dosage forms in the 
stomach or somewhere in the upper intestine until all of 
the drug is released over the desired period of time 
(Baumgartner et al, 2000). The principle of buoyant 
preparation offers a residence time for the dosage form 
and sustained drug release. The various buoyant 
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preparations include micro-balloons, granules, powders, 
capsules, tablets, and laminated films (Sing and Kim, 
2000). Based on the mechanism of buoyancy, two 
distinctly different technologies, i.e., non-effervescent 
and effervescent systems have been utilized in the 
development of floating systems. Non-effervescent 
systems commonly use gel-forming or highly swell-able 
cellulose type hydrocolloids, polysaccharides and matrix 
forming polymers such as polycarbonate, polyacrylate, 
polymethacrylate, and polystyrene. Effervescent 
systems utilize matrices prepared with swell-able 
polymers such as methocel or chitosan and effervescent 
compounds, such as sodium bicarbonate and citric or 
tartaric acid (Rubinstein and Friend, 1994). The various 
buoyant preparations include micro-balloons, granules, 
powders, capsules, tablets, and laminated films. Based 
on the mechanism of buoyancy, two distinctly different 
technologies, i.e., non-effervescent and effervescent 
systems have been utilized in the development of 
floating systems. Non-effervescent systems commonly 
use gel-forming or highly swellable cellulose type 
hydrocolloids, polysaccharides and matrix forming 
polymers such as polycarbonate, polyacrylate, 
polymethacrylate, and polystyrene. Effervescent 
systems utilize matrices prepared with swellable 
polymers such as methocel or chitosan and effervescent 
compounds, such as sodium bicarbonate and citric or 
tartaric acid, or matrices containing chambers of liquid 
that gasify at body temperature (Ritschel, 1991). Mahesh 
et al. (2005) have developed the gastro-retentive drug 
delivery system (GRDDS) for ofloxacin with different 
polymers, such as psyllium husk, HPMC K100M, 
crosspovidone and their combinations in order to get 
the desired sustained release profile over a period of 24 
h. Varshosaz et al. (2006) developed ciprofloxacin 
floating and bioadhesive extended release tablets to 
increase the duration of the drug presence in its 
absorption area.Intragastric floating (IGF) drug delivery 
systems can improve the controlled delivery of drugs 
that have an absorption window by continuously 
releasing the drug for a prolonged period of time before 
drug reaches its absorption site, thus ensuring the 
optimal bioavailability (Bansal, 2003). Lansoprazole is a 
gastric acid pump inhibitor belonging to the class of 
delayed release dosage forms known as proton pump 
inhibitors (PPI’s ) a  dose regimen of PPI’s results in a 
decrease in gastric acid secretion with a subsequent 
elevation in gastric pH.  The objective of the present 
investigation is to prepare and to evaluate IGF tablets of 
lansoprazole, which will help to retain the dosage form 
in the stomach and to increase gastric residence time, 
resulting in prolonged drug delivery in stomach using 
gel-forming polymers such as  
hydroxypropylmethylcellulose (HPMC K4M, HPMC 
K15M). A formulation that shows both combined 
excellent buoyancy and sustained release characteristics 
was chosen for farther in vivo evaluation by X-ray study 
in rabbits for more than 10 h.  
 
 
2.  Materials and mehods  
2.1 Materials 
Lansoprezol (ZPR) was a generous gift sample 
obtained from Cipla pharmaceutical, Mumbai India. 
HPMC K4M and HPMC K15M was a generous gift sample 
received from Colorcon Asia Ltd, Goa India. 
Microcrystalline cellulose was a gift sample received 
from Ozone international, Mumbai India. All other 
chemicals and reagents were of analytical grade and 
purchased locally. 
 
2.2  Methods of preparation of tablet:   
The tablets were prepared according to the method 
followed by Gambier (2007) and Kuksal (2006). 
Lansoprazole, Polymer (HPMC K4M and HPMC K15M), 
Sodium bicarbonate were passed through sieve No.40 
separately. The drug was mixed with the Polymers and 
other ingredients (table 1). Accurately weighed quantity 
of PVPK-30 was dissolved in isopropyl alcohol (IPA) to 
prepare a binder solution. The binder solution was 
added to the dry blend gradually with constant kneading 
to form a homogeneous mass. The dough mass was 
passed through a 2.0-mm sieve and the granular mass 
was allowed to dry at room temperature. The granules 
were passed through a 1.18-mm sieve. These granules 
were lubricated with magnesium stearate and talc and 
compressed into tablet using 10.0mm flat face tooling on 
a tablet compression machine (Remek mini press, India). 
 
2.3  Evaluation of Tablet Characteristics:  
2.3.1  Weight variation 
Twenty tablets were selected random and weighed 
individually. The average weight was calculated. 
Individual weights of the tablets were compared with 
the average weight.   
 
2.3.2 Hardness 
Tablet hardness has been defined as the force 
required to breaking a tablet in a diametric compression. 
Hardness values of the prepared formulations were 
determined using Monsanto hardness tester (n=10).   
The tablet was placed between two anvils of hardness 
tester, force was applied to the anvils, and the crushing 
strength that causes the tablet to break was recorded. 
 
2.3.3 Friability 
Tablets require certain amount of strength or 
hardness and resistance to withstand mechanical shock 
of handling in manufacturing, packaging, and shipping. A 
pre-weighed sample (20 tablets) were placed in the 
friabilator, and operated for 100 revolutions. Thereafter, 
once again weight of the tablets is recorded. The 
percentage friability was calculated based on the loss of 
weight of tablet after keeping in the friabilator.  
 
2.3.4 Thickness 
Thickness of the prepared floating tablets was 
measured using a calibrated dial caliper. Five tablets 
were picked randomly and thickness was measured 
individually. 
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2.3.5 Drug content uniformity 
Twenty tablets were powdered and powder 
equivalent to 30 mg of Lansoprazole was taken. The 
powder was transferred to 100ml volumetric flask. 50ml 
of 0.1 N HCl solutions was added, and stirred for 5 min. 
The volume was made up to 100ml with 0.1N HCl solution 
and filtered. The absorbance was measured at 276 nm, 
against blank prepared in similar manner. The 
experiments were conducted in triplicate. The drug 
content was estimated by an UV spectrophotometer at 
276 nm.  
 
2.4  In vitro buoyancy studies  
The time taken for the tablet to emerge on to the 
surface of the medium is called as floating lag time. 
Duration of the time by which the dosage form 
constantly emerges on the surface of medium is called 
as total floating time.  Tablets were placed in a 100 ml 
flask containing buffer solution of pH 1.2. The time 
needed for a tablet go upward, float on the surface of 
the liquid and floating duration was recorded. 
 
2.5  In vitro dissolution studies 
In- vitro drug release study was carried out using 
USP XXIII, Paddle type dissolution apparatus in 900 ml of 
pH1.2 solution, as a dissolution medium. The paddles are 
rotated at 100 rpm. The Medium was set at 37 ± 0.5ºC. 1 
ml of the sample was withdrawn at predetermined time 
intervals (30 min) for the period of 3 hrs and thereafter 
every hour for 24 hrs. The same volume of fresh medium 
was replaced. The withdrawn samples were diluted with 
10 ml of same medium in volumetric flasks and analyzed 
by an UV spectrophotometer at 276 nm using 0.1 N HCl 
as a blank. The experiments were conducted in triplicate. 
The drug content and percent cumulative of drug 
release were calculated using the equation generated 
from standard calibration curve. 
 
2.5  In vivo radiographic studies 
The optimized formulation F4 was studied with 
regard to buoyancy using radiography. To make the 
tablet X-ray opaque, lansoprazole in formulation was 
replaced with 30 mg of barium sulphate (BaSo4) and the 
tablets were prepared as previously mentioned keeping 
all other ingredients constant. The protocol of in-vivo 
buoyancy studies on rabbits was carried out and 
monitored by a radiographic method. The animal 
experiment was approved by the Animal Ethical 
Committee, BLDEA’s College of Pharmacy, Bijapur, India 
(BLDEA’s COP/IAEC. Dated june 2009-Jan 2010). The 
study was conducted on six albino rabbits of either sex 
weighing between 2–2.5 kg (2.3 ±0.2 kg). The animals 
were housed in individual cages and the experiments 
were conducted in a sanitized room at a temperature 
maintained at around 24 ºC. Food was withdrawn 12 
hours prior to the study with water ad libitum. One 
tablet to each animal was administered through specially 
made oral gastric tube with 25 ml water in fasted state. 
The animals were not allowed to eat or drink throughout 
the study. Before taking X-ray photographs, the 
animals were held in upright posture. The animals were 
exposed to X-ray photography in the abdominal region 
at different time intervals (0, 4, 8, and 12 hours) for 12 
hours. The tablet that remained buoyant on the surface 
of the gastric content was observed visually from the X-
ray photographs. 
 
3.  Results and discussion 
3.1  Characterization of tablets 
The hardness of batches F1-F8 was found to be 
between 4–5 kg cm2 indicating satisfactory mechanical 
strength. The thickness of prepared batches was 
between 2.2±0.3 and 2.7±0.6 mm. The friability was in 
the range of 0.49–0.65 % for all the formulations, which 
was an indication of good mechanical resistance of the 
tablet. The average drug content of tablets (n = 10) 
varied between 95.45 and 98.98%, indicating good drug 
content for the prepared formulations. All the batches 
exhibited uniformity of drug content and fulfilled the 
compendial specifications of the various quality control 
parameters. 
 
 
 
Fig1. In-vitro floating lag time study of F8 
 
3.2 In vitro buoyancy studies 
Lansoprezole tablets were prepared using 
polymers such as HPMC K4M and HPMC K15M.  
Formulations F1-F4 was prepared with HPMC K4M, and 
F5-F8 was prepared with HPMC K15M. Tablets were 
evaluated for physical characteristics such as hardness, 
floating capacity and weight variation.  The floating lag 
time was found between 25±5 and 70±5. The formulation 
F8 has shown very short floating lag time of 25±5 sec. 
(Fig 1).  The sodium bicarbonate was used as a gas 
generating agent in order to float the tablet. The sodium 
bicarbonate induces CO2 generation in the presence of 
dissolution medium (0.1N HCl).The gas generated is 
trapped and protected within the gel formed by 
hydration of the polymer, thus decreasing of the density 
of the tablet below 1gm/mL, and the tablet becomes 
buoyant. The foating duration for the prepared batches 
was in the range of 21.25±0.52 hrs and 24.95±0.34 hrs. 
The formulaion F8 has shown prolonged floating lage 
J.S. Patil, V.B.Biradar, P.R. Biradar, S.S. Shiralashetti, S.C. Marapur & P.B.Gurav J.Food Pharm.Sci (2015), 1-5  
       
4 
time of  24.95±0.34 hrs (Fig 2) when compared to all 
other formulations followed by F4 which has shown 
24.86±0.54 hrs. This indicated that the least amount of 
HPMC K15 M and maximum amount of gas generating 
agent used in F8 are responsible for good floating lag 
time and maximum duration of floating. The floating lag 
time and the duration of floating for the prepared 
tablets are given in Table 2. In general, all the prepared 
tablets floated between 21 to 24 hrs.  
 
 
Fig 2. In-vitro floating duration profile of F8 
 
Fig 3. In vitro dissolution profile of formulations F1- F4 
 
 
Fig 4. In vitro dissolution profile of formulations F5- F8 
 
3.3  In vitro dissolution studies 
The release of lansoprezole was found to be a 
function of the polymer concentration. All formulations 
retarded the release of drug for 24 hrs (figure 3 and 4). 
The effect of HPMC K4M and HPMC K15M at different 
concentrations ranging from 100% to 160% and 80% to 
120% respectively on the release of lansoprezole from 
tablet matrices was studied. Figure 2 and 3 shows the 
drug release profiles from HPMC K4M and HPMC K15M 
matrices, respectively. As the concentration of the 
polymer was increased in the different formulations, the 
rate of drug release was decreased. Finally, the retardant 
effect of the polymer on the drug release can be 
indicated as: HPMC K15M>HPMC K4M. The release of 
the drug from the different formulations can be 
arranged as:  
 
F1<F2<F3<F4<F5<F6<F7<F8. In vitro drug release studies 
revealed that the release of lansoprezole from different 
formulations varies with the characteristics and the 
composition of matrix forming polymers and the 
proportion of gas generating agents. The percent drug 
release was increased as the concentration of gas 
generating agents increased. A reverse trend was 
observed on increasing the polymer concentration. 
 
3.4  In vivo radiographic studies  
After ingesting of the final placebo formulations 
were developed by using barium sulphate in the released 
layer, the tablets were clearly seen in the GIT at different 
time points during the study and the duration of the 
tablet in the stomach and upper part of intestine was 
monitored by radiograph, it can be evidenced by Fig 5. It 
was found that the tablet stayed in the stomach for 12 
hrs. 
 
 
 
 
Fig5. Radiographic images showing the presence of a BaSO4-
loaded floating tablet in the rabbit stomach at different time 
periods (the tablet is indicated with a line drawn by pen). 
 
4.  Conclusions 
The present study was carried out with the aim to 
develop the floating drug delivery with controlled 
release of lansoprazole using HPMC K4M and 
HPMCK15M polymers as the carriers. The preliminary 
evaluation results of the floating tablets were found 
satisfactory. In vitro dissolution studies of the prepared 
tablets showed controlled release for 24 h with fast 
floating lag time and in vivo studies indicated increased 
gastro retention time. Thus, results of the current study 
clearly indicate, a promising potential of the 
lansoprazole floating system as an alternative to the 
conventional dosage form. However, further clinical 
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studies are needed to assess the utility of this system for 
patients suffering from gastric ulcer. 
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Table 1: Composition of lansoprazole floating tablets (mg) 
 
Formulation HPMC K4M HPMC K15M      NaHCO3 DCP PVPK-30 
F1 160 - 10 10 20 
F2 140 - 20 20 20 
F3 120 - 30 20 20 
F4 100 - 40 50 30 
F5 - 120 10 40 30 
F6 - 100 20 50 30 
F7 - 90 30 50 30 
F8 - 80 40 50 30 
All the tablets contain 30 mg lansoprazole, 5 mg magnesium stearate and 5 mg talc. 
HPMC: hydroxypropyl methylcellulose, PVP: polyvinyl pyrrolidone, DCP: dicalcium phosphate, NaHCO3: Sodium bicarbonate 
 
Table 2. Physicochemical properties and floating behavior of tablets  
 
Batch 
code 
Thickness 
(mm) n=20 
Weight variation 
n=20 
Hardness 
(kg/cm2) 
% Friability 
% Drug 
content 
Floating lag 
time (sec) 
Duration of 
floating (hrs) 
F1 2.2±0.3 228.96±0.33 4-5 0.56 96.65 70±5 21.25±0.52 
F2 2.5±0.5 227.86±0.66 4-5 0.57 95.53 60±9 22.65±0.65 
F3 2.6±0.6 227.56±0.88 4-5 0.49 97.54 45±6 23.64±0.35 
F4 2.4±0.4 229.01±0.61 4-5 0.51 98.98 35±6 24.86±0.54 
F5 2.6±0.8 228.21±0.21 4-5 0.65 95.45 55±5 22.02±0.36 
F6 2.7±0.6 227.95±0.69 4-5 0.62 97.28 35±8 23.56±0.56 
F7 2.3±0.4 230.53±0.55 4-5 0.58 96.56 30±4 21.32±0.42 
F8 2.5±0.7 229.25±0.36 4-5 0.56 98.65 25±5 24.95±0.34 
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